Last reviewed · How we verify

Moisview Eye drop

Huons Co., Ltd. · Phase 3 active Small molecule

Moisview is an eye drop formulation designed to treat dry eye disease by providing ocular surface lubrication and potentially reducing inflammation.

Moisview is an eye drop formulation designed to treat dry eye disease by providing ocular surface lubrication and potentially reducing inflammation. Used for Dry eye disease (keratoconjunctivitis sicca).

At a glance

Generic nameMoisview Eye drop
SponsorHuons Co., Ltd.
Drug classOphthalmic lubricant / Dry eye disease therapeutic
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Moisview eye drops work as a lubricating and protective agent for the ocular surface, helping to restore tear film stability and reduce symptoms associated with dry eye disease. The formulation is intended to provide sustained relief by maintaining moisture on the cornea and conjunctiva, potentially incorporating anti-inflammatory or mucoadhesive components typical of advanced dry eye therapeutics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results